In 2021, the homozygous deletion of cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) was introduced as another diagnostic hallmark to identify IDHmut astrocytomas with a worse clinical outcome and hence WHO grade 4 classification [4,5]. This evidence concerns the gene CDKN2A and astrocytoma (excluding glioblastoma).